Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.
Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.
Areas of Expertise (5)
Physicians of Excellence, Orange County Medical Association (professional)
Southern California Rising Star™ (professional)
2015 Neurology — SuperDoctors® edition of Los Angeles magazine
Ruth L. Kirschstein National Research Service Award (professional)
American Federation of Aging Research Glenn/AFAR Fellowship (professional)
University of Southern California: PhD, Molecular Biology 2003
Carol Davila University of Medicine and Pharmacy: MD 1997
- American Board of Psychiatry and Neurology
- Society of Neuro-Oncology
- American Society of Clinical Oncology
- American Academy of Neurology
Media Appearances (7)
Novel approaches to malignant brain tumor treatment aim to overcome familiar challenges
“Achieving effective treatment with minimal side effects is the biggest challenge in the field of malignant brain tumors right now,” Daniela A. Bota, MD, PhD, professor of neurology, vice dean for clinical research and medical director of the comprehensive brain tumor program at University of California, Irvine, told Healio.
A Cancer-Quashing Microbe Emerges from the Deep
Hakai Magazine online
Daniela Bota, then a fellow in neuro-oncology at Duke University in North Carolina, attended the annual conference for the American Association for Cancer Research, where she listened to Nereus scientists present results from their multiple myeloma trial. Bota was searching for potential glioblastoma treatments, and marizomib intrigued her.
UCI Health Research Leads Fight Against COVID-19
Irvine Standard online
“This was extremely timely,” says Dr. Daniela Bota, vice dean for clinical research and medical director of the CCR, which now has 75 principal investigators and 120 clinical researchers on staff. “When COVID-19 hit, we had some advantages.”
Trump brags that he’s helping patients access medical ‘miracles.’ He isn’t.
The Washington Post online
The idea of letting people take a gamble like that has intuitive appeal. But almost a year and a half after the law’s enactment, scholars and reporters looking for evidence of its effectiveness have turned up only a small number of people who have used the law to obtain treatment. Matt Bellina, an amyotrophic lateral sclerosis (ALS) patient who campaigned for the law, has been receiving an experimental therapy still in clinical testing from BrainStorm, the New York-based company has confirmed. Daniela Bota, a neurologist at the University of California at Irvine, helped secure a nonapproved drug through Right to Try for a patient with aggressive brain cancer, she told STAT News (and confirmed to The Washington Post).
Scientists develop a blood test to predict how long patients with the aggressive brain cancer that killed John McCain will live - and it could lead to custom treatments
Daily Mail online
Her family's frantic research brought Amanda to the UCI's Dr Daniela Bota and her 700-person clinical trial for adult patients to undergo treatment with a drug called Marizomib.
Glioblastoma patient's tumor no longer measurable thanks to promising clinical trial
Fox News online
In their search for help, the Johnsons connected with UCI Health neuro-oncologist Dr. Daniela Bota, who is currently leading a clinical trial for 700 newly diagnosed glioblastoma patients.
Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law
A California man with a deadly form of brain cancer is receiving an experimental therapy under the so-called Right to Try law, the first publicly known use of the controversial legislation that was signed into law in May 2018 by President Donald Trump. The treatment, called Gliovac, is a vaccine crafted from the patient’s own cells and tissue taken from other patients with glioblastoma -- the same aggressive tumor that killed John McCain a year after his diagnosis. It’s being provided to the man, who has chosen to remain anonymous for now, by Epitopoietic Research Corp., or ERC, a closely-held Belgian company that is testing it in human trials.
Research Grants (1)
The Mechanisms of Chemotherapy Induced Cognitive Defects
National Institutes of Health (NIH)
Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neuronsMitochondrion
Naomi Lomeli, Kaijun Di, Diana C Pearre, Tzu-Feng Chung, Daniela A Bota
2020 Primary brain tumor patients often experience neurological, cognitive, and depressive symptoms that profoundly affect quality of life. The DNA alkylating agent, temozolomide (TMZ), along with radiation therapy forms the standard of care for glioblastoma (GBM) – the most common and aggressive of all brain cancers. Numerous studies have reported that TMZ disrupts hippocampal neurogenesis and causes spatial learning deficits in rodents; however, the effect of TMZ on mature hippocampal neurons has not been addressed.
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialClinical Cancer Research
David A Reardon, Annick Desjardins, James J Vredenburgh, Donald M O'Rourke, David D Tran, Karen L Fink, Louis B Nabors, Gordon Li, Daniela A Bota, Rimas V Lukas, Lynn S Ashby, J Paul Duic, Maciej M Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A Green, Michael J Yellin, Christopher D Turner, Tibor Keler, Thomas A Davis, John H Sampson
2020 Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glioblastoma.
A Novel Rat Ovarian Cancer Model Developed to Examine Chemotherapy-Related Cognitive ImpairmentsGynecologic Oncology
D. Pearre, N. Lomeli, D. Bota
2020 OBJECTIVES: To describe a novel method of developing an ovarian cancer intraperitoneal (IP) and subcutaneous (SC) xenograft model with the purpose of extrapolating chemotherapy-related cognitive impairments (CRCI) in tumor-bearing rats.
PDCT-17 (LTBK-11). PNOC007: H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Midline GliomasNeuro-Oncology
Timothy Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela Bota, Chetan Bettegowda, Jay-Jiguang Zhu, Fabio Iwamoto, Dimitris Placantonakis, Nina Martinez, J Bradley Elder, George Kaptain, David Cachia, Yaron Moshel, Steven Brem, David Picconi, Nam Tran, Do-Hyun Nam, Chul-Kee Park, Joseph Landolfi, David Tran, Rohan Ramakrishna, Karen Fink, Deborah Heros, Gelareh Zadeh, Garth Nicholas, Vivek Mehta, H Ian Robins, Clark Chen, Marshall Pitz, Jason Heth, Seema Nagpal, Michael Pearlman, Manmeet Ahluwalia, Nimish Mohile, Ryan Merrell, David Schiff, Reid Thompson, Raphael Davis, David Macdonald, Thian Kheoh, Fairooz Kabbinavar, Alexander Lossos, Michael Vogelbaum
2019 To assess within a multi-center trial the safety of H3.3K27M specific peptide vaccine in combination with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ diffuse midline gliomas.
Management of low-grade glioma: a systematic review and meta-analysisNeuro-Oncology Practice
Timothy J Brown, Daniela A Bota, Martin J van Den Bent, Paul D Brown, Elizabeth Maher, Dawit Aregawi, Linda M Liau, Jan C Buckner, Michael Weller, Mitchel S Berger, Michael Glantz
2018 Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma.